This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Epilepsy  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 41 words of the full text and any section headings.

In Reply: We thank Drs Racoosin and Knudsen for pointing out these important, additional safety issues that have recently arisen. We also thank them for clarifying that oligohydrosis, not hyperhydrosis, is the cause of rare fevers in children who receive zonisamide.

Suzette M. LaRoche, MD
suzette_laroche@emoryhealthcare.org

Sandra L. Helmers, MD
Department of Neurology
Emory University,
Atlanta, Ga

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291:2074.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Safety of Newer Antiepileptic Drugs
Judith A. Racoosin and James F. Knudsen
JAMA. 2004;291(17):2074.
EXTRACT | FULL TEXT  

The New Antiepileptic Drugs: Scientific Review
Suzette M. LaRoche and Sandra L. Helmers
JAMA. 2004;291(5):605-614.
ABSTRACT | FULL TEXT